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EXAMINATION of  sputum  provides  a  direct  method  to
investigate  airway  inflammation  non-invasively  in
particular  Th1  (IL–2,  IFN–g )  and  Th2  (IL–4,  IL–10)
cytokine production.
IL–2, IL–4, IL–10 and IFN–g cytokine were studied
in  induced  sputum  mononuclear  cells  of  asthmatic
patients.
Sputum  induction  was  performed  on  10 patients
and  10  normal  controls.  Basal  and  mitogen-stimu-
lated cytokine production was determined in induced
sputum  T-cell  culture.  Supernatants  were  collected
and assayed not only with specific ELISA but also with
polymerase chain reaction (PCR) techniques.
Data showed a significantly higher production of
IL–10 by both the ELISA and the RT-PCR techniques in
asthmatic  patients  compared  with  sputum  mono-
nuclear cells from healthy controls. IL–4 production
was detected at a low level using the ELISA method in
asthmatic  patients.  The  RT-PCR  analysis  detected  a
significantly IL–4-mRNA expression in all asthmatic
patients,  compared  with  controls.  Results  of  IL–10
and  IL–4  mRNA  expression  were  reproducible.  We
did not find any alteration in the expression of the
type  1  derived  cytokines  (IL–2  and  IFN–g )  in  asth-
matic patients or in healthy controls.
Our study showed a tendency of induced sputum
mononuclear  cells  to  express  a  Th2-like  cytokine
pattern in acute exacerbation of asthmatic patients,
where  IL–10  and  IL–4  are  synthesized  in  larger
amounts. The combination of sputum induction as a
non-invasive tool to explore the lung and the identi-
fication  of  disease-associated  cytokine  expression
and of specific cytokine mRNA should help elucidate
mechanisms  of  the  immunologically  mediated
inflammatory responses in asthma.
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Introduction
Chronic  mucosal  inflammation  plays  an  important
role  in  the  pathogenesis  of  asthma.  Several  airway
cells  such  as  mast  cells,  macrophages, eosinophils,
endothelial or epithelial cells, and lymphocytes have
been postulated to participate in  this inflammatory
response.  Cytokines  and  mediators  produced  by
these airway inflammatory cells could provide a local
mechanism  to  induce,  amplify  or  modulate  the
ongoing inflammation.
T-lymphocytes play a vital role in the regulation and
coordination  of  immune  responses.  Activation  of
T-cells  leading  to  secretion  of  cytokines  may  be
involved  in  the  pathogenesis  of  asthma. Activated
T-cells  can  be  recognized  by  the  expression  of
particular surface markers, such as the interleukin–2
(IL–2) receptor (CD25), the human leukocyte antigen
HLA–DR and  the very late  activation antigen VLA–
1.1,2 T-cells may orchestrate inflammatory responses
to  inhaled  allergen  and  other stimuli  in  asthma by
production of several cytokines.
T-cell derived cytokines IL–4, IL–5 and interferon-
g: (IFN–g) are intimately involved in the regulation of
IgE production which is fundamental to the pathogen-
esis of allergic asthma.3–5 Furthermore, several stud-
ies have suggested a role for T-cell derived cytokines in
the  initiation  of  eosinophil  inflammation.6,7 Inter-
leukin–5 (IL5), granulocyte-macrophage colony stim-
ulating  factor (GM-CSF)  and IL–3 have pronounced
effects on eosinophil tissue localisation, prolongation
of survival, maturation and activation. The description
of  a subset of murine T helper cell  clones (termed
TH2) that produces IL–5, IL–3 and GM-CSF together
with IL–4 or IL–2 raised the possibility that activation
of  a Th2-like  subset  of  CD4+ T-lymphocytes  might
contribute  to  eosinophil  infiltration.8,9 Indeed,  in
atopic  individuals,  allergen  specific  T-cell  clones
produce  a Th2  like  pattern  of  cytokines,  whereas
other  antigen  specific T-cell  clones  from  the  same
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Induced  sputum  provides  a  direct  method  to
investigate airway inflammation non-invasively. When
sputum cannot be produced spontaneously, it usually
can  be  successfully  induced  by  inhalation  of  an
aerosol of hypertonic saline. Sputum cell counts can
be reproducible, reliable and valid. New methods of
examination using cytospins of dithiothreitol-treated
sputum  improve  reliability  and  reduce  the  time  of
examination.11 The cells can also be stained immuno-
histochemically  for  activation markers and  the  cell
supernatant can  be  used  to  investigate  fluid  phase
constituents. The use of sputum  allows us to study
inflammatory  mononuclear  cells  and  programmed
cell death in asthma.11,12 Its application to the study
of Th1  and Th2  in  asthma  disease should  improve
understanding of the pathogenesis.
The present paper describes the role of induced
sputum T-lymphocytes in the inflammatory response
of different forms of asthma patients, focusing mainly
on the analysis of the Th1 (IL–2 and IFN–g) and Th2
(IL–4  and  IL–10)  lymphocyte,  using  the  ELISA
method and mRNA analyses. The role of Th1 and Th2
cells in mediating the selective infiltration of inflam-
matory cells will be discussed.
Patients and methods
Patients
Induced  sputum  samples  were  collected  from  10
successive patients with asthma. All were inpatients,
admitted  for  an  acute  wheezing  exacerbation  of
dyspnoea, usually as an emergency. The sample was
obtained the day after admission. A precise history of
the  patient  was  subsequently  obtained,  and  after
recovery functional  respiratory tests and eventually
skin tests were carried out. Patients with the follow-
ing diagnoses were excluded: concomitant infectious
pneumonia,  tuberculosis,  interstitial  lung  diseases,
bronchiectasis,  lung  cancer,  and  associated  acute
pathologies:  cardiac,  renal,  liver,  or  neurological
diseases. The induced sputum from 10 healthy sub-
jects  (mean  age  28.7  yrs;  range  22–36),  who  had
normal pulmonary radiographs and showed no clin-
ical  signs  of  respiratory  disease,  acted  as  controls.
Informed consent was obtained from all patients.The
study was approved by the local Ethics Committee.
Serum  IgE  levels  were  elevated in  most  patients
(range 110–940U/ml). In healthy controls the serum
IgE levels were < 100U/ml.
Sputum induction
After  the  inhalation  of  salbutamol  (2  ´ 200mg),
subjects  were  asked to  inhale  sterile, pyrogen-free,
hypertonic saline in increasing concentrations for a
duration of 10min. The hypertonic saline was nebu-
lized  via  an  ultrasonic  nebulizer.  Subjects  were
encouraged to cough throughout the procedure. Most
patients were able to expectorate an adequate sample
(7ml and more) within the first 10min.
Sputum processing
In  order  to  reduce  salivary  contamination,  plugs
were  selected  and  transferred  into  an  Eppendorf
tube.  A  freshly  prepared  10%  solution  of  dithio-
threitol  (1ml)  (DTT)  was  added.  The  tube  was
vortex  mixed  and  the  sputum  was  incubated  for
5min  at room temperature, filtered through 52mm
nylon  gauze  to  remove  debris  and  mucus,  and
subsequently  centrifuged  at 450´ g for 10min. The
cell  pellet  was  resuspended  in  phosphate-buffered
saline (PBS)  in  a volume  equal  to the sputum  plus
DTT solution volume. Total cell counting was carried
out in a haemocytometer and the cell concentration
was adjusted to 1.0 ´ 106 cells/ml. Cytospins were
prepared by adding 75ml cell suspension into Shan-
don  II  cytocentrifuge  cups  (Shandon  Southern
Instruments)  and  spun  for  8min  at  500rpm. Two
slides were stained with Wright-Giemsa for an over-
all  differential  cell  count  of  leukocytes,  bronchial
epithelial  cells  and  squamous  cells.  Slides  were
coded and counted blind by two investigators. None
of the cytospins contained > 5% squamous epithelial
cells. For cell differentiation, 400 nucleated cells per
slide were counted and expressed as a percentage of
intact  round  nucleated  cells,  excluding  the  squa-
mous epithelial cells.
T-cell culture
Lymphocytes were isolated by Ficoll-Hypaque (Phar-
macia, Uppsala, Sweden) density gradient centrifuga-
tion and washed twice with PBS at 4°C, as we have
recently  reported.5 The  cell  pellet  expressed  more
than 80%  CD3-positive cells as determined by  anti-
CD3 monoclonal antibody (Becton Dickinson).
T lymphocytes were diluted in RPMI 1640, and 1ml
aliquots  were  deposited  in  2ml  wells  of  a  24-well
plate (Falcon). Basal and mitogen stimulated [phyto-
haemagglutinin (PHA; Sigma, St Louis,M final concen-
tration of 5mg/ml); and lipopolysaccharide (LPS, from
Salmonella  enteritidis;  Sigma,  final  concentration
25mg/ml)]  conditions  were  evaluated.  The  plates
were incubated at 37°C in a CO2 atmosphere. After
culture periods of 24h and 48h the contents of the
wells were harvested, spun at 2000´ g for 2min and
the supernatants were collected and stored frozen at
–80°C until use. Sputum induced-cells were used for
mRNA analysis.
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Culture  supernatants  were  collected  after  24h  to
measure the IL–4 and IFN–g contents and after 48h
to evaluate IL–10.
Supernatant  cytokine  concentrations were  deter-
mined by ELISA (Immunotech, Bio-Care, Tunis). The
positivity  thresholds  were  10pg/ml  for  IL–2,
0.08U/ml for IFN–g, 1.5pg/ml for IL–4 and 3pg/ml
for IL–10 (Immunotech, Bio-Care, Tunis).
RNA extraction
After incubation for an appropriate time, cells were
isolated by  brief  centrifugation  and  then  stored  in
1ml Trizol (Gibco, at –80°C until further processing.
RNA extraction was performed using phenol chloro-
form  extraction and ethanol precipitation following
the manufacturer’s instructions. The RNA content of
the solution was quantified using the optical density
(OD)  at  260nm  measured  on  a  SECOMAN  spec-
trophotometer and the RNA aliquots were stored at
–80°C  until  analysed.  The  ratio  260/280nm  was
always more than 1:8.
Reverse transcription and PCR
cDNA was synthesized from oligo-dT-primed RNA by
reverse transcription (RT)  with M–MLV  superscript
reverse transcriptase (Gibco). The total RNA mixture
was incubated with 200  UM-MLV  reverse transcrip-
tase, 20U RNasin, 0.5 mM, dNTPs, 25mg/ml primer
dT,  10 mM  dithiothreitol,  50 mM Tris-HCI  pH  8.3,
75 mM  KCI and 3 mM  MgCl2, in  a final  volume  of
20ml for 50min at 42°C. The final cDNA product was
stored at –20°C for subsequent cDNA amplification
by PCR.
Reaction mixtures for PCR of b-actin and cytokines
contained  2ml  sample,  0.5 mM  dNTP,  0.5U  Taq
polymerase,  1mg  of  each  primer,  50 mM Tris-HCI,
3 mM  MgCI2,  75 mM  KCI  0.01%  gelatin  in  a  final
volume of 100ml. PCR was performed on a thermal
cycler (Personal cycler Biometra, Germany). Reaction
times for g-actin were 94°C 1min. 65°C 1min, and
72°C 1min for 28 cycles, followed by 10min exten-
sion at 72°C. Reaction times for cytokine PCR were as
follows: for IL–4 and IL–10, 94°C 1min, 65°C 1min
and 72°C 1min; for IL–2 and IFN–g, 94°C 1min, 55°C
1min and 72°C 1min for 38–40 cycles followed by
10min extension at 72°C for all cytokines.
Primer sequences for the internal control, g-actin.
were 59-TAC ATG GCT GGG GTG TTG AA–39 for the
downstream primer. and 59-AAG AGA GGC ATC CTC
ACC CT–39 for the upstream primer. Primer sequen-
ces for cytokines were as follow: for IL4, 59-CTT CCC
CCT  CTG TTC TTC  CT–39 for  the  59 primer,  and
59TTC  CTG TCG AGC  CGT TTC AG–39 for  the  39
primer; for IL–10, 59-ATG CCC CAA GCT GAG AAC
CAA GAC CCA–39 for the 59 primer, and 59-TCT CAA
GGG  GCT  GGG TCA  GCT ATC  CCA–39 for  the  39
primer; for IL–2, 59-AAC TCC TGT CTT GCA TTG CAC
TA–39, for the 59 primer, and 59-TTG CTG ATT AAG
TCC  CTG  GGTC–39 for  the  3  primer;  for  IFN–g,
59AGT TAT  ATC TTG  GCT TTT  CA–39 for  the  59
primer, and 59-ACC GAA TAA TTA GTC AGC TT–39 for
the 39 primer. The primer sequences were chosen in
two different  exons. These primer  sequences  were
confirmed to specifically amplify the corresponding
cytokine  cDNA  by  Southern  blot  analysis  using  a
fluorescein-labelled  internal  probe.  cDNA  products
were visualized by gel electrophoresis in 20% agarose
after  ethidium  bromide  staining.  A  cDNA  positive
control, a negative control and a DNA ladder were run
with  all  PCR  reactions.  Amplifications  resulted  in
200–400 bp product, as determined by electrophore-
sis  on  2%  TEA  agarose  gel  containing  bromide
ethidium.
Dot-blot analysis
PCR  products  were  denatured  and  vacuum  dot
blotted  onto  Hybond-N  membrane  (Amersham,
France).  Specific  probes  were  39-end  labelled  with
fluorescein–11-dUTP using the ECL 39-oligolabelling
reagents (RPN 2130; Amersham). The sequences of
internal probes were as follows: for b-actin, 59CCA
ACT  GGG ACG ACA TGG AGA AAA –  39:  for  IL–2,
59GGC  CAC AGA ACT  GAA ACA TCT–39;  for  IL–4,
59-CTC GGT GCT CAG AGT CTT CTG CTC T–39; for
IL–10, 59-CAG GTG AAG AAT GCC TTT AAT AAG CTC
CAA CAG AAA GGC ATC TAC AAA GCC ATG AGT GAC
TTT GAC ATC–39; for IFN–g, 59-ATT TGG CTC TGC
ATT TTT CT GT –39.
Following hybridization to the dot blots and incuba-
tion  with  anti-fluorescein-horseradish  peroxidase
(HRP) conjugate, detection of the bound peroxidase
was performed using hydrogen peroxide and luminol.
The amount of each spot was determined by densito-
metry analysis. All of the cytokine PCR products were
analysed  comparatively  to  the  amount  of  b-actin
detected in the same mRNA sample. All samples were
checked  in  the  same  test  run  for  each  cytokine
analysed.  Separate  cycle  course  experiments  con-
firmed  linearity  of  amplification  for  b-actin  and
cytokine cDNA over 20–35 cycles and 30–45 cycles,
respectively. For each PCR, linearity of amplification
relative to cDNA dilutions was over 1/5–1/20 for IL–4
and  IFN–g,  1/5–1/40  for  IL–2,  1/5–1/80  for IL–10
and g-actin.
Statistical analysis
The  distributions  of  cytokine  concentrations  are
reported  as  their  median  values,  first  and  third
Th1/Th2 cytokines in asthma
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tions  were  made  with  the  non-parametric  Mann-
Whitney U-test, with the level of significance set at
0.05.  Tests  were  performed  with  the  statistical
software STATISTICA. Correlations were determined
by  linear  regression  and  Spearman’s  rank
correlation.
Results
Cytokine production
Th1 cytokines
In the absence of exogenous stimuli, the spontaneous
production of IL–2 was at normal values in asthmatic
patients and healthy controls (Table 1). After 24h in
the presence of LPS + PHA, IL–2 levels were higher in
supernatants  from  both  populations,  with  asthma
patients’  IL–2  concentrations  being  significantly
higher than those of healthy controls (Table 1).
As for IL–2, basal IFN–g production was compara-
ble  for  both  populations.  LPS  +  PHA  stimulation
increased these concentrations, without differences
between patients and healthy controls (Table 1).
Th2 cytokines
Basal  IL–10  production  was  significantly  higher  in
asthmatic patients than healthy controls. Significantly
higher  amounts  of  IL–10  were  also  detected  in
samples  from  asthmatic  patients  compared  with
controls under culture conditions (Table 1).
Spontaneous  IL–4  production  differed  between
asthmatic patients and healthy controls (Table 1), but
significance was not notable. Mitogen-activated spu-
tum  T-cells  from  both  populations  generated
enhanced  IL–4  concentrations,  and  low  statistical
difference between groups was observed (Table 1).
All asthmatic patients stimulated sputum T-cells pro-
duced high amounts of IL–4.
Expression of cytokine mRNA in sputum
mononuclear cells from asthmatic patients and
healthy controls
Because the spontaneous secretion of IL–4 cytokine
in sputum mononuclear cells is very low by ELISA, we
studied the expression of cytokine genes in sputum
cells with a semi-quantitative PCR technique.  Cyto-
kine-specific cDNA were normalized to the intensity
of the b-actin product as a standard marker.
Data revealed spontaneous IL–4 mRNA expression
in all asthmatic patients, whereas normal donors in
most cases did not show specific signals (p < 0.0001)
(Fig. 3). Representative examples of autoradiographs
showing signals from sputum cells of asthmatics and
normal donors after PCR amplification and specific
hybridization are shown in Fig. 1.
The technique of RT-PCR amplification used in this
study  remained  semi-quantitative;  IL–10  mRNA
expression appeared to be significantly enhanced in
asthmatic patients compared with healthy controls (p
< 0. 001) (Fig. 3).
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Table 1. IL–2, IFN–g, IL–4 and IL–10 cytokine production by sputum T-cells from asthmatic patients and healthy controls
Cytokine Healthy controls
Basal LPS+PHA
Asthmatic patients
Basal LPS+PHA
IL–2 14.79 16.92 11.62 43.6*
(10.58–22.75) (12.42–68.32) (10.39–36.93) (12.43–125.30)
IFN–g 0.163 17.824 0.172 22.183
(0.092–0.746) (8.53–42.29) (0.128–4.96) (3.56–98.32)
IL–10 22.7 1407 64.3* 3058.6**
(2.36–75.46) (870–1913) (37.41–131.6) (214.7–6592)
IL–4 1.912 34.25 2.21 67. 35*
(1.66–2.94) (2.63–98.4) (1.97–7.94) (32.6––110.9)
Results are given as medians and ranges, and expressed in pg/106 sputum T-cells. Results for IFN–g are expressed in U/106 sputum T-cells.
*Statistical significance comparing asthmatic patients versus healthy controls: p < 0.01 is considered significant.
FIG. 1. Expression of mRNA for IL–4 and IFN–g in sputum
mononuclear  cells  from  asthmatic  patients  and  healthy
controls.  The  cytokine  polymerase  chain  reaction  (PCR)
product were dot-blotted, hybridized with a specific probe,
and the results were shown comparatively to those of b-actin
signals.Data shown in Fig. 2 indicate that the expression of
mRNA for IFN–g and IL–2 in asthmatic patients did
not differ at all from healthy controls (p = 0.42 and p
= 0.36, respectively for IFN–g and IL–2).
Using  RT-PCR  techniques,  our  results  show  a
clear  enhancement  of  spontaneous  IL–10  mRNA
expression  in  asthmatic  patients  over  healthy  con-
trols. In addition, mRNA expression of the Th1 type
derived  cytokines  (IL–2  and  IFN–g)  in  the  same
experimental conditions did not differ between spu-
tum  induction  cells  of  healthy  controls  and  asth-
matic patients.
Correlations
There is no correlation between the amount of IL–
4 mRNA expression, IL–10 mRNA expression, IFN–
g mRNA  expression  and  serum  IgE  levels.  An
inverse correlation is observed between IL–2 mRNA
expression  and  serum  IgE  levels  (r =  –0.72,  p =
0.007).
A significant correlation between IL–2 and IFN–g
production  was  established  only  when  patients’ T
lymphocytes were stimulated (r = 0.57, p = 0.0003).
Discussion
T-helper lymphocytes type 2 (Th2) are considered to
play an essential role in orchestrating the inflamma-
tory response associated with asthma. Th2 lympho-
cytes express cytokine-associated cell differentiation,
eosinophil  differentiation,  mucus  secretion,  airway
smooth muscle hyperreactivity, and mast cell hyper-
plasia. The aim of the present study was to determine
the  cytokine  pattern  during  acute  exacerbation  of
asthma,  using  the  non-invasive  method  of  induced
sputum  combined with  the polymerase  chain reac-
tion. Our study focused on the cytokine production in
culture supernatant sputum-T cells, of IL–2, IFN–g,
IL–10 and IL–4.
Total  cell  count  was  elevated  in  patients  with
asthma compared with healthy controls, as we have
recently  reported.12 Sputum  cells  of  patients  with
asthma  expressed  high  percentages  of  eosinophils
and  lymphocytes.  The  lymphocytes  were  in  the
majority CD3-positive (T lymphocytes). The leukocyte
count  and  phenotype  of  the  lymphocytes  showed
Th1/Th2 cytokines in asthma
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FIG. 2. Individual expression of mRNA for IFN–g and IL–2 in
asthmatic  patients and healthy controls  in sputum  mono-
nuclear cells. The expression of mRNA is shown as percen-
tages relative to the signals of b-actin.
FIG. 3. Individual expression of mRNA for IL–4 and IL–10 in
asthmatic  patients and healthy controls  in sputum  mono-
nuclear cells. The expression of mRNA is shown as percen-
tages relative to the signals of b-actin.that  sputum  traduced  an  inflammatory  state  in
patients  with  asthma.  Our  results  obtained  from
analysing induced sputum in asthma patients reflect
the inflammatory status of the bronchi.12
Th2 T-lymphocytes, characterized by the ability to
produce cytokines such as IL–4 and IL–10, have been
largely  implicated  in  the  pathogenesis  of  allergic
inflammation. In support of these results, studies on
sputum  cells  from  asthmatic individuals show  high
levels of IL–4 and IL–10 in culture supernatants of
mononuclear cells. These results were corroborated
with  the  expression  of  mRNA  expression  of  Th2-
associated cytokines IL–4 and IL–10. Interleukin–10
secretion by monocytes and lymphocytes was respon-
sible  for  the  heightened  immunoglobulin  produc-
tion.13 IL–10  production  was  also  found  to  be
enhanced in disorders characterized by prominent B
lymphocyte hyperactivity, which results in increased
production  of  immunoglobulin.14 IL–10  was  origi-
nally characterized as a factor generated by Th2 cells
that inhibits cytokine synthesis by Thl cells.15 How-
ever,  several  other  cell  types  have  been  further
identified as a source of IL–10, including CD4+ and
CD8+ T-lymphocytes, natural killer (NK) cells, mono-
cytes/macrophages, B  cells,  mast  cells,  eosinophils,
and bronchial epithelial cells.16 The concept that IL–
10  acts  as  an  anti-inflammatory  molecule  emerged
from its capacity to down-regulate the synthesis of a
broad spectrum  of  proinflammatory  cytokines  pro-
duced  by  monocytes/macrophages  and  neutro-
phils.17
The  immunosuppressive  properties  of  IL–10  are
mainly related to inhibition of antigen-presenting cell
(APC)  functions.  Indeed,  IL–10  downregulates  the
expression of class II major histocompatibility com-
plex (MHC) and costimulatory molecules (e.g. inter-
cellular adhesion molecule–1 (ICAM–1) on the mem-
brane of monocytes/macrophages and inhibits their
synthesis of inflammatory cytokines (IL–1, IL–6, IL–8
and  tumour  necrosis  factor-a (TNF-a).  The  latter
effect  was  also  documented  on  alveolar  macro-
phages.18 The inhibition of the local synthesis of TNF-
a secretion and  the  down-regulation  of pulmonary
vascular  ICAM-I  expression  were  shown  to  be
involved  in  the  protective  effects  of  IL–10  against
immunoglobulin  G (IgG)  immune  complex-induced
lung injury.
The increased expression of  IL–4  mRNA in  asth-
matic-induced  sputum  cells  that  we  observed  is
consistent with  the  findings  obtained by  Brown  et
al.19 in peripheral blood cells. Cytokine requirement
for primary generation of the Th2 response in the lung
was dependent on IL–4.20The ELISA method that we
used displayed only 2.21pg/ml in culture supernatant
sputum  mononuclear  cells;  one  could  suggest  that
sputum mononuclear cells needed more days stimula-
tion  and  the  sensitivity  of  the  method  remained
insufficient for the detection of cytokine production.
The lack of spontaneous IL–4 secretion reported by
other  authors19 in  peripheral  circulation  indicated
that this method is not representative of an inflamma-
tory process localised in the lung. Cells obtained by
induced sputum were more representative of the in
situ inflammation in asthmatic patients, and use  of
the  mRNA-PCR  method  was  important.  Our  study
ruled  out  the  possibility  of  a  lack  of  correlation
between  gene  transcription and active synthesis  of
the relevant protein, since the increased spontaneous
mRNA  expression  for  IL–4  as  detected  by  PCR  is
compatible with the secretion of this cytokine.
IFN–g protein in sputum culture supernatant cells
from  asthmatic patients was comparable to healthy
controls, after mitogenic stimulation. This result was
consistent with other data.21
Our  results  demonstrated  a  tendency  of T  cells
from a group of asthmatic patients to express a Th2
pattern with a high level of expression of IL–4 and
IL–10  cytokines.  However,  the  classified Th2  cyto-
kines  reported in  this  paper can  also be produced
by Th1 cells such as IL–10.22 The study of IL–4 and
IL–10  production  in T  cells  from  induced  sputum
could  be  the  description of  localised inflammatory
process. A similar study should be corroborated with
local  B  cell-IgE  production.  Such  investigation
should give information about the local T and B cell
interaction.
Given that IgE production is considered to involve
the production of Th2 cytokines, we were surprised
at the lack of correlation of IL–4 mRNA, IL–10 mRNA
and serum IgE levels. Other groups have shown that
high and low IgE responders are under the control of
IL–4 expression, and that IL–4 production correlates
with serum IgE.23,24 The lack of correlation between
serum IgE level and IL–10 mRNA expression could be
explained  by  the  fact  that  IL–10  induces  B  cell
proliferation and production of isotypes IgM, IgG and
IgA,  with  no  effect  on  IgE  synthesis.25 In  these
conditions,  the  IL–10/IL–2  and  IL–10/IFN–g were
examined (data not given). Enhanced ratios attribut-
able  to  high  IL–10  production  were  found  for  all
asthmatic patients, and might trigger the B lympho-
cyte hyperactivity. Low ratios reflecting elevated IL–
10 and IL–2 or IFN–g levels could be taken as marker
of inflammation and tissue injury. Such interpretation
could help us to understand the modulation of Th1
and Th2 cytokines.
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Matzinger26 proposed the hypothesis that antigenic
stimuli presented to a mucosal barrier interface direct
the immune response towards the Th2 phenotype and
that the normal response is effectively to inhibit these
processes through a variety of pathways,  including
tolerance, anergy and apoptosis. Th2 cytokine profiles
were significantly more resistant to activation-induced
apoptosis and bcl–2 expression was reported to be
higher  in  Th2  cells  than  in  those  producing Th1
cytokines.24 Our recent results concerning apoptosisin acute exacerbation of asthma showed an increased
bcl–2  expression  in  induced  sputum  mononuclear
cells  and  the  percentage  of  apoptosis  was
decreased.12 Resistance to activation-induced apopto-
sis may explain the expansion of cells producing Th2
cytokines.27
Our results provided indirect evidence in vivo for
increased mRNA expression for IL–4 and IL–10. The
Th1 and Th2 cytokine profile may be significant in the
analysis  of  clinical  allergic  responses  in  asthmatic
patients. An improved understanding of the cellular
and molecular mechanisms resulting in Th2 responses
has  suggested  potential  therapeutic  strategies  to
inhibit Th2 responses associated with asthma. Further
studies will  need  to  determine whether alternative
approaches to inhibit Th2 cells are practical in human
subjects. The Th2-induced sputum cell appears to be a
useful, non-invasive tool to explore the inflammation
of asthma.
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